Reaction
Retinal Artery Occlusion reporting signals
As of the last recalculation, Retinal Artery Occlusion appears in 2,489 FAERS reports alongside 36 co-occurring drug terms. The strongest observed disproportionality signal is AFLIBERCEPT (PRR 46.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Aflibercept | 161 | 46.1 | 46.3 |
| Ranibizumab | 104 | 34.1 | 34.3 |
| Faricimab | 32 | 33.4 | 33.6 |
| Triamcinolone Acetonide Ointment Usp, 0.05% | 76 | 28.0 | 28.1 |
| Bupivacaine | 25 | 22.6 | 22.7 |
| Triamcinolone Acetonide | 78 | 21.8 | 21.8 |
| Tranexamic Acid | 21 | 19.9 | 19.9 |
| Dorzolamide Hydrochloride And Timolol Maleate | 10 | 10.6 | 10.6 |
| Melphalan Hydrochloride | 30 | 10.1 | 10.1 |
| Brinzolamide | 9 | 8.7 | 8.7 |
| Brimonidine Tartrate | 18 | 8.5 | 8.5 |
| Prednisolone Acetate | 10 | 8.1 | 8.1 |
| Moxifloxacin Hydrochloride | 19 | 7.9 | 7.9 |
| Baricitinib | 9 | 7.8 | 7.8 |
| Lidocaine Hydrochloride | 55 | 7.8 | 7.8 |
| Sildenafil Powder, | 32 | 7.6 | 7.6 |
| Lidocaine Hydrochloride And Epinephrine Bitartrate | 46 | 7.3 | 7.3 |
| Atropine | 7 | 7.1 | 7.1 |
| Sildenafil | 45 | 6.6 | 6.6 |
| Testosterone Cypionate | 7 | 6.6 | 6.6 |
| Moxifloxacin | 11 | 6.6 | 6.6 |
| Lidocaine 4% | 42 | 6.5 | 6.5 |
| Amiodarone Hydrochloride | 8 | 6.0 | 6.0 |
| Amikacin | 11 | 5.4 | 5.4 |
| Drospirenone And Ethinyl Estradiol | 28 | 5.3 | 5.3 |
| Bevacizumab | 75 | 5.2 | 5.2 |
| Pitavastatin Calcium | 6 | 4.9 | 4.9 |
| Sildenafil Citrate | 71 | 4.8 | 4.8 |
| Dabigatran Etexilate Mesylate | 34 | 4.0 | 4.0 |
| Rivaroxaban | 90 | 3.7 | 3.7 |
| Dabigatran Etexilate | 33 | 3.6 | 3.6 |
| Abemaciclib | 7 | 2.9 | 2.9 |
| Eltrombopag Olamine | 8 | 2.9 | 2.9 |
| Lenvatinib | 11 | 2.8 | 2.8 |
| Apalutamide | 3 | 2.1 | 2.1 |
| Tirzepatide | 30 | 1.6 | 1.6 |